Cer Sheridan
Senior Vice President, Chief Medical Officer
biotechnology
biocryst
Switzerland
Biography
Dr. William Sheridan joined BioCryst in July 2008. Dr. Sheridan is a seasoned biotechnology professional. During a 15-year tenure at Amgen, Dr. Sheridan organized and led the company's U.S. Medical Affairs function, making significant contributions to the successful launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta® and Sensipar®, and led several product development teams. At Amgen, Dr. Sheridan held titles at the Vice President level in North American Medical Affairs, International Medical Affairs, Global Health Economics and Outcomes Research, U.S. Medical Affairs, and Product Development. He played an integral role in building Amgen's domestic and international medical affairs functions and in forming the health economics and outcomes unit. Dr. Sheridan earned his MB BS degree (M.D. equivalent) at the University of Melbourne in Victoria, Australia. Dr. Sheridan is a board-certified fellow of the Royal Australasian College of Physicians (FRACP), with a sub-specialty in medical oncology, and a Fellow of the American College of Physicians.
Research Interest
biotechnology
